Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data Article (Faculty180)

cited authors

  • Scott, Jeffrey A; Lennerz, Jochen; Johnson, Melissa Lynn L; Gordan, Lucio N; Dumanois, Robert H; Quagliata, Luca; Ritterhouse, Lauren L; Cappuzzo, Federico; Wang, Brandon; Xue, Mei; Vasudevan, Anupama; Varughese, Prateesh; Vaidya, Varun; Gart, Mike; Dorrow, Natalie; Gierman, Hinco J; Choksi, Rushir J

description

  • Identification and targeting of actionable oncogenic drivers (AODs) in advanced non-small-cell lung cancer (NSCLC) has dramatically improved outcomes. However, genomic testing uptake is variable and hampered by factors including slow turnaround time, frequently resulting in initial non-tyrosine kinase inhibitor (TKI) treatment. We investigate how this behavior affects outcomes.

authors

publication date

  • 2024

published in

start page

  • 145

end page

  • 153

volume

  • 20